Boehringer Ingelheim GmbH
http://www.boehringer-ingelheim.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Boehringer Ingelheim GmbH
Sanofi’s $500m COVID-19 Deal Comes Four Years Too Late
But it rescues embattled Novavax.
Lupin’s Confidence Over Mirabegron Relaunch Doesn’t Convince Analyst
While Lupin is “truly excited with the potential” ahead, the uncertainty around upcoming product launches paints a different financial picture.
Asia Deal Watch: Ono Calls On PRISM BioLab’s Capabilities
Plus transactions involving Nissan Chemical/Sanwa Kagaku, Memel/Therabest, Chugai/Alnylam, Takeda/Kumquat, Nxera/Handok, 3SBio/CStone and deals in brief.
A Job Well Done: AstraZeneca Bids Adieu To Vaxzevria As Demand Dries Up
The voluntary withdrawal of the license for the UK major's COVID-19 vaccine is due to a surplus of available updated jabs from other companies that target new variants and is not connected to the mis- and disinformation being peddled on the internet and elsewhere on very rare adverse events.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abexxa Biologics Inc
- AMAL Therapeutics SA
- ICD Therapeutics
- NBE Therapeutics AG
- SSP Co., Ltd.
- Vira Therapeutics GmbH (Vira T)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice